| 52 Week Rng | - |
| Market Cap | - |
| Avg Volume | - |
| 1M Volatility | - |
| Short Ratio | - |
| P/E Ratio (TTM) | - |
| P/E Ratio (Fwd) | - |
| P/B Ratio | - |
| Div & Yield | - |
Juuse • Aalto Investment management game (Fall 2021) • Dec 2021
Momentum, no longer last weeks winner. Closing position
alpha_investors • Aalto Investment management game (Fall 2021) • Nov 2021
According to our strategy, this company has parameters of P/E < 15, small cap ($ 500 million - $ 2 billion), and a sector of healthcare.
IRAM2021Team2 • IRAM 2021 • Feb 2021
EBS is a manufacturer for vaccines and other medical products, and is a key manufacturer for J&J's COVID vaccine candidate, which we expect will be approved shortly (either the single dose arm tomorrow or the double dose arm in about a month). EBS has a 5 year contract to manufacture the COVID vaccine along with contracts with the state and federal government to manufacture vaccines for over $1B in revenues upon approval. It trades at 12x forward PE which we believe is a good valuation.
qminnich • Stockfuse Continuum (US) • Aug 2020
Automatic trade executed by Stockfuse to ensure margin compliance.
Jay_Z.the.one.by.the.door.2nd. • Morton Micro 2019-20 - 2nd Semester • Apr 2020
Companies working against the Coronavirus should see an increase.
TriiStockteteers • OLD|Aalto Investment Management Game (Spring 2020) • Mar 2020
Automatic trade executed by Stockfuse to ensure margin compliance.